Heinonen, Aaro
Rauhala, Minna
Isokuortti, Harri
Kataja, Anneli
Nikula, Milaja
Öhman, Juha
Iverson, Grant L.
Luoto, Teemu
Article History
Received: 22 March 2022
Accepted: 18 June 2022
First Online: 7 July 2022
Declarations
:
: The study was approved by the Ethics Committee of the Pirkanmaa Hospital District, Tampere, Finland (ethical code: R10027). All data was collected retrospectively without contacting the patients, therefore no written informed consent was obtained or required.
: Grant Iverson, Ph.D., serves as a scientific advisor for NanoDX®, Sway Operations, LLC, and Highmark, Inc. He has a clinical and consulting practice in forensic neuropsychology, including expert testimony, involving individuals who have sustained mild TBIs. He has received past research funding from several test publishing companies, including ImPACT Applications, Inc., CNS Vital Signs, and Psychological Assessment Resources (PAR, Inc.). He acknowledges unrestricted philanthropic support from ImPACT Applications, Inc., the Mooney-Reed Charitable Foundation, the National Rugby League, and the Spaulding Research Institute. None of the above entities was involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Teemu Luoto has received speaker’s fees from Orion Corporation, Novartis Finland, and the Finnish Medical Society Duodecim. Teemu Luoto has also accepted research grants from the Finnish Brain Foundation sr, the Emil Aaltonen Foundation sr, the Maire Taponen Foundation, the Science Fund of the City of Tampere, and the Finnish Medical Society Duodecim. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.